Regulation is not background noise. In European life sciences, it is part of the commercial model.
This section tracks the policy, access, compliance, and approval changes that shape adoption, timing, and strategic options.
The paradigm in healthcare is shifting: instead of “see a doctor when things go wrong”, some start-ups are betting the future lies in “continuous health monitoring for when things haven’t yet gone wrong”. The US model is blazing ahead; Europe is watching with interest and caution. The US playbook: Function Health Here’s the rundown for…
The VCs, public funds, and CVCs writing cheques in European healthtech (2025 edition) Healthtech funding in Europe is accelerating again. After a cautious 2023, investment rebounded to $4.8 billion in 2024, and Q1 2025 alone brought in $4.3 billion. Healthtech now captures 30 to 35% of all venture activity across the continent. But who’s actually…
What’s scaling, who’s paying, and why you should care Let’s start with a question.What do Oura, Sword Health, and Doctolib have in common? If you said “healthtech unicorns” you’re technically right, but that’s not the real answer.The real answer: they’re European, they’re growing like weeds, and most investors or founders still talk about them like…
The €100 Million Bet on Retail Diagnostics Omnichannel in MedTech usually means a half-baked app, an email campaign, or a portal nobody uses. ZEISS changed the script. In March 2025, ZEISS launched its EyeCare Network and quietly took a €10 million stake in Ocumeda, a tele-ophthalmology platform connecting 700 optical stores to 300,000 patients. Retail…
A deep dive into the EU Commission’s latest findings on AI in healthcare. What MedTech founders and investors need to know in 2025.
The Promise Genomics is drowning in data. A single human genome contains over 3 billion base pairs, and personalised medicine requires mapping not just one genome but entire populations. Quantum algorithms promise to search and analyse these vast datasets faster than classical methods, identifying subtle gene–disease correlations that underpin cancers or rare conditions. The pangenome…
Your pacemaker is now an endpoint. Attackers read release notes too. Why Devices + AI Are Tricky Case in Point The 2017 firmware recall for ~465k Abbott (St. Jude) pacemakers shows the stakes, a patch was issued to mitigate RF cybersecurity vulnerabilities (Read more). Regulatory Overlap Secure Design Patterns Ship devices with a patch plan,…
Pharma wants real-world data; adversaries want it more. Case Studies Risk Hotspots Mitigations Your real-world data strategy is only as strong as your real-world security.
VCs love TAM slides. Users love not being breached. Why Startups Under-Secure Investors Waking Up Diligence Questions Minimal Security Stack Secure runway beats growth at any cost, especially in health.
Europe wrote the rules. Now it has to monetise them. The EU Stack Why It Can Be a Moat Risks & Tensions If Europe aligns security, standards, and procurement, trust becomes a market advantage — not a compliance tax.